The ATTACK Project

The ATTACK Project

Adoptive engineered T cell Targeting to Activate Cancer Killing (ATTACK) is a European Union Framework Programme Six (FP6) Integrated Project.

The five year ATTACK Project involves a consortium of 17 partners over Europe, 2 partners in Israel and is coodinated by Robert Hawkins at The University of Manchester.

Objectives

The pre-clinical programme focuses upon the development of immune cell therapies to target cancer.  Specifically the use of gene therapy approaches to modify T cells - a particular subtype of immune cell.  T-cells are part of the immune defense machinery which naturally protects against infections and some cancers.  T cells can be used to treat some malignant disease but many cancers avoid destruction by the immune system.  Using state of the art technologies to target the T-cells by introducing artificial receptors, it is hoped to provide these cells with tumour specificity.  This consortium will collaborate on this process of "engineering T-cells."
... Read More...

Goal

The programme will enhance understanding of how cancer cells evade the immune system in order to improve T cell mediated immunotherapy to fight a broad range of cancer.

Specific Scientific Areas for Development include

... Read more on the Workpackages...

The consortium background

The approach adopted by the consortium stems from original research by Professor Zelig Eshhar in Israel.

The partners in the project include experts who have developed key aspects of engineered T-cells, immunology and tumour biology from key research institutions across Europe.

The partners have a long record of EU based collaboration. Co-ordination of the project will be aided by an International Advisory Board of external experts.

Funding

100% European Commission
Contract Number: LSHC-CT-2005-018914

Further information

 

Cellular Therapy Of Cancer Symposium

Location: London

Date:  27th February to 2nd March 2013